Skip to main content

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Completed · Phase 3 · NCT01712490

Conditions: Hodgkin Lymphoma

At a glance

Research payments reported, 2025
$255,754
U.S. investigators named
62
Sites paid
47
Planned or actual enrollment
1,334

About the trial

Sponsor
Takeda (with Seagen Inc.)
Tested
brentuximab vedotin (drug), doxorubicin (drug), bleomycin (drug), vinblastine (drug), dacarbazine (drug)
Dates
Started 2012-11-09; completion 2026-02-02
Results posted
Yes

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

From ClinicalTrials.gov, last updated 2026-02-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $255,754 in research payments for this study in 2025 (135 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.